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Abstract 
Glucocorticoids, widely used in inflammatory disorders, rapidly increase bone fragility 
and, therefore, fracture risk. However, common bone densitometry measurements are not 
sensitive enough to detect these changes. Moreover, densitometry only partially 
recognizes treatment-induced fracture reductions in osteoporosis. Here, we tested 
whether the reference point indentation, technique could detect bone tissue properties 
changes early after glucocorticoid treatment initiation.  
After initial laboratory and bone density measurements, patients were allocated into 
groups receiving calcium + vitamin D (Ca+D) supplements or anti-osteoporotic drugs 
(risedronate, denosumab, teriparatide). Reference point indentation was performed on the 
cortical bone layer of the tibia by a handheld device measuring Bone Material Strength 
index (BMSi). Bone mineral density was measured by dual-energy x-ray absorptiometry 
(DXA).  
While Ca+D-treated patients exhibited substantial and significant deterioration, 
risedronate-treated patients exhibited no significant change, and both denosumab- and 
teriparatide-treated participants exhibited significantly improved BMSi 7 weeks after 
initial treatment compared to baseline; these trends remained stable for 20 weeks. In 
contrast, no densitometry changes were observed during this study period.  
In conclusion, our study is the first to demonstrate that reference point indentation is 
sensitive enough to reflect changes in cortical bone indentation following treatment with 
osteoporosis therapies in patients newly exposed to glucocorticoids.  
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Introduction 
Glucocorticoid treatment is widely used and effective for treating a number of immune 
and inflammatory disorders (1), but it can have deleterious effects on the bone. These 
effects, which are complex and only partially understood (2-5), eventually lead to rapid 
deterioration of bone strength with a subsequent increase in fracture risk detectable very 
early after initiating therapy (6-10). Bone mineral density (BMD) measurements have been 
recommended for guiding clinical decisions (11). However, in glucocorticoid-treated 
individuals, bone fractures occur at higher BMD levels than in individuals with 
postmenopausal or senile osteoporosis; these fractures can also occur very early, well 
before BMD evaluation can detect any significant decline (12,13). Furthermore, BMD can 
only partially measure the reductions in fracture risk (i.e., the effect on bone strength) 
after treatment with different anti-osteoporotic drugs (14,15). Thus, more sensitive clinical 
measurements based on other contributions to bone strength are needed. The BMD-
independent glucocorticoid effect on bone fracture resistance (i.e., increased bone 
fragility) is a prime example of deterioration in bone tissue quality (16,17), which is defined 
as a mass-independent change in intrinsic material properties that contributes to the bone 
fragility observed in osteoporosis (6,7) and other conditions (18,19). Despite this need for 
measuring the contribution of bone properties at a tissue level to bone fragility, direct 
assessment of bone tissue mechanical properties has not yet been used in patients because 
mechanical testing requires sampling of bone specimens, not feasible in clinical practice. 
Moreover, longitudinally monitoring the BMD-independent effect of most available anti-
osteoporotic drugs on fracture reduction (i.e., bone fragility improvement) (13,14) is also 
unfeasible. On one hand, repeated measurements of tissue components cannot be 
performed because of the invasive nature of the methods. On the other, imaging 
techniques for measuring bone microarchitecture and assessing bone strength are 
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restricted to research centers with advanced technologies, and these techniques have the 
disadvantages of long response periods (20-23) or a low sensitivity for detecting changes 
(24). 
Reference point indentation (RPI) is a recently developed microindentation technique 
(Fig. 1) for assessing bone mechanical characteristics at the tissue level (25). The data 
obtained by this technique in animal studies has been correlated with bone toughness in 
some (26) but not all (27) experiments and can detect treatment-induced changes in bone 
material properties (28). In patients, reference point indentation can discriminate between 
fracture cases and controls (29) and can identify bone tissue deterioration in cases of 
atypical fracture (30). A new hand-held RPI instrument has been developed for convenient 
clinical use (31) and has successfully detected bone quality deterioration in diabetic 
patients independent of BMD (32). Although one theoretical advantage of reference point 
indentation is the ability to kinetically monitor changes in bone mechanical properties, 
available data from cross-sectional studies in humans has not yet formally demonstrated 
this potential. Here, we addressed this potential by evaluating the efficacy of reference 
point indentation for longitudinal studies in a patient population receiving glucocorticoid 
therapy, which is well known to cause rapid deterioration in bone strength. We further 
tested whether reference point indentation could detect tissue-level responses to various 
anti-osteoporotic medications. 
 
Materials and Methods 
Study population 
A clinical series of consecutive cases were included in the study within 4 weeks of 
initiating glucocorticoid treatment. The required glucocorticoid dose was at least 5 
mg/day prednisone (or equivalent) during the observation period. Patients were 
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considered ineligible if they had been previously exposed to systemic glucocorticoids, 
anti-osteoporotic medications, radiation therapy, or other drugs that could potentially 
affect the bone. Additionally, patients were ineligible if they were previously diagnosed 
with chronic endocrine, hepatic, renal, or malabsorptive disease; Paget’s disease of bone; 
neoplasia; or any condition that, in the opinion of the investigator, might interfere with 
the study protocol. Table 1 details the baseline characteristics of the study cohort, 
including background conditions. 
All groups received Ca+D supplementation. According to Spanish guidelines (33), patients 
of age below 65 and T-score >-1.5 were assigned to Ca+D only and teriparatide was 
indicated in severe osteoporosis cases (T-score of -3.5 or below with or without fractures, 
or a T-score of -2.5 or below plus a fragility fracture). The remaining patients were 
assigned to the risedronate group unless any contraindications or upper gastrointestinal 
complaints occurred, in which case patients were assigned to the denosumab group.  
Reference point indentation method 
At baseline, patients underwent a general laboratory workup, and BMD was measured at 
the lumbar spine and hip using DXA (Hologic QDR 4500 SR™, Hologic, Bedford, MA). 
Bone indentation measurements were carried out at baseline (visit 0 [V0]) and again at 7 
weeks (V1) and 20 weeks (V2) later using an Osteoprobe™ instrument (Active Life 
Scientific, Santa Barbara, CA). After skin disinfection, local anesthesia (2–3 cc of 1% 
mepivacaine) was subcutaneously administered on the anterior face of the mid-shaft of 
the right tibia using a 3-cc syringe with a 28-gauge needle. The test probe was then 
inserted through the skin into contact with the bone surface using the dominant hand to 
stabilize the needle on insertion and during repositioning. Careful attention was taken to 
avoid touching above the luer lock/needle guide not only to maintain sterility but also to 
maintain the integrity of the measurement value obtained by the procedure. Importantly, 
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caution was exercised to ensure that the Osteoprobe needle had gone through the 
periosteum and was perpendicular (30) to and in contact with the bone surface prior to 
taking measurements. The outer housing of the instrument was then lowered with the non-
dominant hand over a 1–2-second period until the trigger mechanism was released. 
During compression, a 10 N force was generated to establish the initial reference point at 
the cortical surface, followed by an additional trigger force of 30 N to obtain the 
experimental measurement. A total of 8 reference point indentations, each separated by 
at least 2 mm, were obtained in 2 parallel lines of 4 indents each in the center of the long 
axis of the anterior surface of the tibial bone. In most cases, only one skin insertion was 
necessary, and the probe could be displaced for successive measurements without new 
piercings. The measurement from the first indentation was systematically disregarded 
because the insertion process could have affected it. The instrument software gave clear 
visual indication of aberrant readings, which occurred if normalcy to the cortical surface 
was not maintained. Following patient measurements, 5 indentations were performed for 
normalization on a poly(methylmethacrylate) (PMMA) cube using the same probe and 
the same observer. Results were expressed as BMSi units defined as 100 times the ratio 
of the harmonic mean of the 5 penetrations of the test probe into a PMMA calibration 
cube to each penetration of the test probe into the cortical bone. The software provided 
by the manufacturer detects if an individual measurement, either in the bone or in the 
PMMA, deviates from the average indentation value in the tibia as well as from the 
reference calibration value of 100 for the calibration cube. Outlier values detected this 
way are not introduced in the calculation of the results. BMSi units are dimensionless, 
distinguishing them from strength measurements in the specialized mechanical 
engineering sense, which is measured in units of force per unit area.   
 9 
Both Bland-Altman plots(34) and intraclass correlation coefficient (0.73, 95% CI 0.46 to 
0.99, p for significant correlation = 0.0012) suggest good correlation and no significant 
departure from expected confidence limits. In addition, no trend bias is observed in Bland-
Altman plots either. All measurements in the current study were obtained by the same 
investigator (LM) to minimize the possible effect of inter-observer variation. The 
procedure took lees than 5 minutes and caused only minimal discomfort to the patient 
during administration of the local anesthetic. In our experience with this and other 
ongoing studies in our center on over 650 patients and volunteers, no complications 
occurred; moreover, patient discomfort after the procedure was mild and did not require 
administration of pain medication except in a single case of mild local skin infection in a 
kidney transplant recipient from another study, which was subsequently resolved after a 
short course of antibiotics. Local skin infection, significant local edema, or thick 
subcutaneous adipose tissue at the site of indentation were considered as 
contraindications for this technique. 
For ethical reasons, the following rescue condition was stipulated for patients receiving 
Ca+D only: if a >10% decrease in BMSi was observed at V1, these patients were switched 
to an active treatment and excluded from further follow up. 
Power calculation  
Assuming a standard deviation of 17.5% change in BMSi variation at 7 weeks (according 
to pilot data), 43 subjects were necessary to recognize a statistically significant difference 
greater than or equal to 8.75% (0.5 standard deviations) in paired measurements with 90% 
power, accepting an alpha risk of 0.05 in a two-sided test.  
Statistical analysis 
Wilcoxon tests for non-parametric related samples were used to evaluate significant 
changes in BMSi between visits. Non-parametric unrelated sample tests were used to 
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evaluate unadjusted differences in BMSi changes between treatment groups. Multivariate 
linear regression models were fit to estimate the association between a given anti-
osteoporotic drug and BMSi changes after adjusting for the following potential 
confounders: age, gender, and cumulative dose of systemic glucocorticoids.  
Study approval 
The study protocol was approved by our institution’s Committee of Ethics and 
Investigation (Reference number: 2013/5141/I), and signed informed consent was 
obtained. 
 
Results 
A total of 52 patients were enrolled within 4 weeks of initiating glucocorticoid treatment. 
Following Spanish guidelines (33), 19/52 (36.5%) patients received 1000 mg/day calcium 
plus 800 IU/day 25-hydroxy (OH) vitamin D supplementation only (Ca+D); 14/52 
(26.9%) received risedronate; 14/52 (26.9%) received denosumab; and 5/52 (9.6%) 
received teriparatide, all at approved and commercially available doses. The mean  
standard deviation (SD) glucocorticoid dose/day at baseline ranged from 33.4  17.1 mg 
prednisone (or equivalent) in the Ca+D group to 43.9  21.2 in the risedronate group. 
Similarly, the cumulative dose during the entire observation period ranged from 2.9  2.0 
g in the Ca+D group to 5.5  4.2 g in teriparatide group (Table 1). Patients in the active 
treatment groups (risedronate, denosumab, and teriparatide) were older and exposed to a 
higher initial oral glucocorticoid dose than those in the Ca+D group. As expected, at 
baseline, in an unadjusted linear regression model, using Ca+D users as the reference 
group, bisphosphonate users had similar BMSi (p for a difference = 0.64), whilst both 
teriparatide and denosumab users had significantly lower BMSi by 12.97 (95%CI 4.34 to 
21.60, p=0.004) and 7.08 (95%CI 1.04 to 13.13, p=0.023) units respectively. 
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Compared to baseline, BMSi significantly declined in the Ca+D-treated patients (median 
[inter-quartile range] = -11.4% [-19.3% to -6.2%]; P = 0.002), did not significantly 
change in risedronate-treated patients (-1.1% [-8.1% to +11.0%]; P = 0.83), and 
significantly increased in both the denosumab- (+9.4% [+4.9% to +16.0%]; P = 0.001) 
and teriparatide-treated patients (+16.8% [+10.7% to +26.2%]; P = 0.043) at the first 
follow-up visit (V1) after 7 weeks. These differences incorporated multivariate 
adjustments for potential confounders (Table 2) and remained stable thereafter until the 
second follow-up visit (V2) at 20 weeks (Fig. 2). Of the Ca+D-treated patients, 10/19 
(52.6%) were switched to bisphosphonate treatment at V1 after meeting the rescue 
condition stipulated in the Methods section. A total of 9, 14, 5, and 14 patients in the 
Ca+D, risedronate, teriparatide, and denosumab groups, respectively, reached the V2 
follow up. In contrast to the changes observed by reference point indentation 
measurements, no changes in BMD were observed between baseline and V1 or V2 for 
any group (data not shown). Based on the data in Fig. 2 showing the evolution of BMSi 
in each treatment group relative to baseline, glucocorticoid treatment led to obvious bone 
indentation properties decline in Ca+D-treated patients. Risedronate exhibited a mere 
stabilizing effect on glucocorticoid treatment, and both teriparatide and denosumab 
demonstrated a positive effect on bone BMSi.   
 
Discussion 
Taken together, this study demonstrates for the first time that changes in cortical bone 
indentation properties, at the tissue level, can be tracked longitudinally using the reference 
point indentation technique in patients exposed to systemic glucocorticoid treatment. 
These changes occur very early (within the first few weeks) after starting glucocorticoids, 
well before BMD imaging by dual-energy x-ray absorptiometry (DXA) can detect any 
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alteration. Our findings are consistent with the early increase in fracture incidence 
observed in glucocorticoid-treated patients.  
This observation builds a strong case for using RPI and BMSi to longitudinally assess 
bone tissue properties. Additionally, the observed rapid response is intriguing. Although 
our present observations cannot provide mechanistic explanation for this finding, we 
might speculate on some influence of glucocorticoids in the propensity of the bone to 
open microscopic cracks (35), which is ultimately the mechanism underlying the 
generation of clinical fractures at the tissue level, perhaps affecting bone matrix (35) 
although no data support this.  
These results reveal striking BMSi changes in patients receiving various anti-osteoporotic 
treatment regimens. Such responses, ranging from stabilization to clear improvement, 
suggest that currently available drugs maintain or enhance bone tissue mechanical 
strength. Our data also show that monitoring these responses is clinically feasible using 
the reference point indentation method. These findings open the possibility of developing 
new therapies that more selectively affect bone tissue properties; thus, more personalized 
treatment can be achieved by targeting different components of bone strength.  
Results are reported in Bone Material Strength index (BMSi) units, a direct measure of 
the in vivo bone tissue mechanical competence to applied mechanical force, and is 
calculated as the inverse of the normalized indentation distance. Exactly how BMSi 
relates to the specialized quantities measured by conventional mechanical testing is a 
current research focus, although clinical trials will ultimately determine its relevance.  
Since the present work constitutes a proof-of-concept study, our findings have several 
limitations as an open-label, non-randomized design. For instance, effectively comparing 
the efficacy of the different drugs is not possible. Baseline values were, given the design 
of the study and the treatment allocation following the guidelines, much lower in the 
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teriparatide-treated patients than in the other groups. Phenomena like, for example, 
regression to the mean cannot be ruled out. Nonetheless, we demonstrate here the 
feasibility of measuring BMSi in patients, indicating that the reference point indentation 
technique is suitable for use in research and eventually in clinical practice. In particular, 
we show that the technique is minimally invasive, safe, and convenient for both the 
patient and physician. Fig. 1 depicts the footprint of a microindentation mark on the bone 
surface, which is equivalent in magnitude to naturally occurring features. Furthermore, 
changes in bone tissue properties can be detected as soon as 7 weeks after treatment 
initiation and remain stable thereafter, suggesting that most changes observed at the tissue 
level occur very early during treatment. Finally, measurements are taken in cortical bone; 
while trabecular deterioration, as a consequence of glucocorticoids, has been extensively 
assessed, cortical bone also suffers from the deleterious effect of these drugs (36-40). 
Therefore, the effect of the drugs at a tissue level can also be traceable in cortical bone 
as, in fact, our results suggest. 
In conclusion, reference point indentation can measure very early changes in BMSi in 
patients initiating glucocorticoid treatment as well as the differential effects of various 
pharmacologic therapies. These results open new possibilities to explore the effects of 
various interventions on bone mechanical properties at the tissue level in the clinic, either 
for diagnosis and monitoring or developing new therapies.  
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Figure legends 
 
 
Figure 1 Osteoprobe indentation in bone to measure BMSi. (a) Clinical test with the 
Osteoprobe on a patient performed on the mid-diaphysis of the tibia. (b) Schematic 
illustrating the representative indentation depth of the test probe in bone. (c) Cross-section 
of an indentation on a cadaver bone scanned on the microtomography beamline at the 
Advanced Light Source, Lawrence Berkeley National Lab (Berkeley, CA) (courtesy of 
John Jameson). Note that the size of the indentation is comparable to naturally occurring 
irregularities on the bone surface. 
 
Figure 2 Bone Material Strength index (BMSi) values at V0 (baseline), V1 (7 weeks), 
and V2 (20 weeks) for the 4 groups expressed as the percentage change vs. baseline. Error 
bars represent the 25th, 50th, and 75th percentiles of BMSi normalized by baseline.†P = 
0.001; # P = 0.002;  ¶P = 0.043; & P = 0.043; §P=0,043; ‡ P = 0.028;  ⁕ : ns (P values 
vs. baseline).  For the Ca+D group, the change between V1 and V2 (dashed line) is biased 
by the exclusion of those patients (10/19) that suffered a decline, according to the rescue 
condition. 
 
 
 
 
 
Table 1 Patient characteristics at baseline. 
 
  Ca+D Ris TPTD Dmab 
Age (yrs)  55.3 (17.9) 66.1 (17.0) 69.8 (8.0) 58.9 (12.8) 
Gender (men)  11 (57.9%) 10 (71.4%) 1 (20.0%) 5 (35.7%) 
Background 
disease 
Horton’s 3 (18%) 1 (7%) 0 (0%) 1 (7%) 
PMR 2 (11%) 5 (36%) 1 (20%) 0 (0%) 
Sarcoidosi
s 
3 (18%) 1 (7%) 1 (20%) 3 (21%) 
Rheumatoi
d Arthritis 
1 (6%) 0 (0%) 0 (0%) 0 (0%) 
Adult Still’s 
disease 
2 (11%) 0 (0%) 0 (0%) 0 (0%) 
Vasculitis 1 (6%) 3 (21%) 0 (0%) 1 (7%) 
Others 7 (39%) 4 (29%) 3 (60%) 9 (65%) 
Height (m)  1.68 (0.11) 1.65 (0.08) 1.59 (0.10) 1.62 (0.10) 
Weight (kg)  69.9 (9.5) 71.9 (12.9) 70.8 (13.7) 74.5 (14.9) 
BMI  24.7 (2.8) 26.3 (4.5) 27.8 (2.4) 28.2 (4.5) 
Fragility fracture  0 1 3 2 
Lumbar spine 
BMD (g/cm2) 
 1.06 (0.13) 1.04 (0.23) 0.83 (0.19) 0.93 (0.21) 
Femoral neck 
BMD (g/cm2) 
 0.83 (0.13) 0.75 (0.14) 0.62 (0.12) 0.72 (0.15) 
Total hip BMD  0.98 (0.14) 0.91 (0.14) 0.79 (0.13) 0.89 (0.29) 
Initial GC dose 
(mg/d) 
 33.4 (17.1) 43.9 (21.2) 41.0 (17.5) 36.8 (15.9) 
25 OH vit D 
(ng/mL) 
 20.6 (11.0) 19.8 (14.6) 42.2 (2.2) 28.2 (9.3) 
Cumulative GC 
dose (g) 
 2.9 (2.0) 4.8 (2.3) 5.5 (4.2) 4.1 (1.4) 
 
Ca+D = calcium + vitamin D; Ris = Risedronate; TPTD = Teriparatide; Dmab = 
Denosumab; Horton’s = Horton’s arteritis; PMR = Polymyalgia Rheumatica; BMI 
= Body Mass Index; BMD = Bone Mineral Density; GC = Glucocorticoids; 25 OH 
vit D = 25-hydroxy vitamin D.  
 
 


